Evaluation of monoclonal idiotypic-specific antibodies as clearing antibodies for enhancement of target localisation by tumour-specific monoclonal antibodies: diversity of effects in nude mice with human tumour xenografts.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Author(s): Pimm MV;Pimm MV; Gribben SJ
  • Source:
    European journal of nuclear medicine [Eur J Nucl Med] 1992; Vol. 19 (6), pp. 436-40.
  • Publication Type:
    Journal Article; Research Support, Non-U.S. Gov't
  • Language:
    English
  • Additional Information
    • Source:
      Publisher: Springer Verlag Country of Publication: Germany NLM ID: 7606882 Publication Model: Print Cited Medium: Print ISSN: 0340-6997 (Print) Linking ISSN: 03406997 NLM ISO Abbreviation: Eur J Nucl Med Subsets: MEDLINE
    • Publication Information:
      Publication: Heidelberg : Springer Verlag
      Original Publication: Heidelburg, Springer International.
    • Subject Terms:
      Antibodies, Anti-Idiotypic* ; Radioimmunodetection*; Animals ; Humans ; Mice ; Mice, Nude ; Neoplasm Transplantation ; Time Factors ; Tissue Distribution ; Transplantation, Heterologous
    • Abstract:
      Three tumour-specific monoclonal antibodies (MoAbs) showed localisation in human tumour xenografts in nude mice, although the tumour discrimination was limited by the survival of a greater proportion of the MoAb in the blood and body as a whole. An attempt was made to increase tumour discrimination by the subsequent administration of syngeneic idiotypic-specific MoAbs (anti-id) directed against the first antibodies, in the expectation of clearing excess of the first MoAb from the circulation. With one MoAb (NCRC-2), its anti-id (NCRC-60) did effectively clear it from the blood, and, at least within a few hours, the tumour-to-blood ratios were increased. After longer periods, however, the tumour levels of NCRC-2 were also reduced, and the tumour discrimination was no longer increased. With another MoAb (NCRC-23) the tumour levels were reduced to a greater extent than were the blood levels in mice treated with its anti-id (NCRC-59), so that rather than being increased the tumour discrimination was actually reduced to about a third of that in control mice. With a third MoAb (NCRC-48), there was no effect on the tumour or blood levels within a few hours of injection of its anti-id (NCRC-62), and so there was no short-term effect on tumour discrimination. Subsequently, however, the tumour levels were slightly reduced, while the blood levels increased in mice treated with anti-id compared with control mice, so that the tumour-to-blood ratios decreased.(ABSTRACT TRUNCATED AT 250 WORDS)
    • Comments:
      Comment in: Eur J Nucl Med. 1992;19(6):385-6. (PMID: 1618228)
    • References:
      J Immunother (1991). 1991 Aug;10(4):278-85. (PMID: 1657128)
      Br J Cancer. 1981 May;43(5):582-7. (PMID: 6941806)
      Cancer Immunol Immunother. 1987;25(1):10-5. (PMID: 2439201)
      Toxicol Appl Pharmacol. 1991 Apr;108(2):183-93. (PMID: 2017749)
      Biochem Biophys Res Commun. 1978 Feb 28;80(4):849-57. (PMID: 637870)
      J Immunol Methods. 1991 May 17;139(1):83-90. (PMID: 1710253)
      Cancer Res. 1990 Feb 1;50(3):563-7. (PMID: 2297697)
      J Nucl Med. 1987 Oct;28(10):1604-10. (PMID: 3498807)
      Cancer Res. 1991 Oct 15;51(20):5461-6. (PMID: 1913665)
    • Accession Number:
      0 (Antibodies, Anti-Idiotypic)
    • Publication Date:
      Date Created: 19920101 Date Completed: 19920806 Latest Revision: 20190824
    • Publication Date:
      20221208
    • Accession Number:
      10.1007/BF00177371
    • Accession Number:
      1618235